Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...